Maudsley Prescribing Guidelines

Last updated

The Maudsley Prescribing Guidelines (also known by the abbreviation MPG) is a referenced prescribing guideline for psychotropic drugs.

Contents

History of publication

Originally the MPG was produced for local readership in Bethlem Royal Hospital and Maudsley Hospital in London. [1] The 5th edition was the first to be published commercially in 1999 by Martin Dunitz. [1] The 6th (2001) and 7th (2003) were also published by Martin Dunitz. [2] [3] In 2004, Martin Dunitz were subsumed into Taylor and Francis Group and the 8th edition was published under this imprint in 2005. [4] Taylor and Francis then became part of Informa Healthcare who published the 9th edition in 2007 and the 10th edition in 2009. [5] [6] The MPG is revised every two years or so and the 11th edition was published in 2011 by Wiley Blackwell. [7] The 12th edition was published on 17 April 2015 and is available in paperback, as an App and as an e-book. [8] It was edited and written by Professor David Taylor (Maudsley Hospital, UK), Carol Paton (Oxleas Mental Health Trust, UK) and Professor Shitij Kapur (Institute of Psychiatry, Psychology & Neuroscience, UK). Numerous translations have been published. Its guidance is based on primary research, NICE guidance and Cochrane reviews. [9]

The 13th edition was published on 18 May 2018 (in paperback, Kindle and as an App). [10] David Taylor continued as lead author and editor, and was joined by co-authors Thomas Barnes (Imperial College, London) and Allan Young (King's College, London). Japanese and Spanish translations were released in 2019.

The Maudsley Guidelines in Psychiatry 13th Ed is available as an App for all operating systems: https://bookstore.medhand.com/products/the-maudsley-prescribing-guidelines-in-psychiatry.

The 14th Edition was published in June 2021. Italian and Japanese translations followed in 2022. Professor David Taylor continues as lead author and editor.

The 15th edition will be published in March 2025.

Maudsley Prescribing Guidelines International Conference

Attracting delegates from across the world, the Maudsley Prescribing Guidelines International Conference contains the latest evidence-based research and developments in psychiatry. In July 2012, an inaugural conference "Outlining the evidence behind the guidance" was held to celebrate the 11th edition followed by a second conference in September 2014 to launch the 12th edition with the theme "Getting up-to-date: assimilating the latest evidence into practical guidance". Both conferences were attended by over one hundred delegates from around the world and provided the opportunity to hear written guidelines presented by the contributors and to participate in a question and answer session.

The third Maudsley Prescribing Guidelines International Conference "From evidence to practice" was held on Monday 17 December 2018 to celebrate the publication of the 13th edition. [11] Over 200 clinicians attended; more than 50 from outside the UK.

The fourth Maudsley Prescribing Guidelines International Conference Clinical Psychopharmacology in the time of COVID was held remotely on Wednesday 20th October 2021. Coinciding with publication of the 14th edition, the lead editors of the Guidelines and other key contributors, many of them leaders in their fields, have outlined the evidence behind the guidelines.

The fifth Maudsley Prescribing Guidelines International Conference Assuring Evidence-based Prescribing in Mental Illness – the expanding Maudsley Guideline series will be held on 10th April 2025 at the Institute of Psychiatry, Psychology and Neuroscience. This will be a hybrid event: in-person and online.


The Maudsley Practice Guidelines For Physical Health Conditions in Psychiatry

The 1st edition of The Maudsley Practice Guidelines for Physical Health Conditions in Psychiatry was published on 1 October 2020 by Wiley Blackwell (available in paperback). [12] David Taylor, Fiona Gaughran (King's College London), and Toby Pillinger (King's College, London) are co-editors, bringing together contributions from 125 clinicians in the fields of general medicine, surgery, and psychiatry. The text provides evidence-based and practical guidance regarding management of physical health conditions seen commonly in patients with serious mental illness.

Related Research Articles

<i>British National Formulary</i> Pharmaceutical reference book for the UK

The British National Formulary (BNF) is a United Kingdom (UK) pharmaceutical reference book that contains a wide spectrum of information and advice on prescribing and pharmacology, along with specific facts and details about many medicines available on the UK National Health Service (NHS). Information within the BNF includes indication(s), contraindications, side effects, doses, legal classification, names and prices of available proprietary and generic formulations, and any other notable points. Though it is a national formulary, it nevertheless also includes entries for some medicines which are not available under the NHS, and must be prescribed and/or purchased privately. A symbol clearly denotes such drugs in their entry.

<span class="mw-page-title-main">Pimozide</span> Chemical compound

Pimozide is a neuroleptic drug of the diphenylbutylpiperidine class. It was discovered at Janssen Pharmaceutica in 1963. It has a high potency compared to chlorpromazine. On a weight basis it is even more potent than haloperidol. It also has special indication for Tourette syndrome and resistant tics.

<span class="mw-page-title-main">Loxapine</span> Antipsychotic medication

Loxapine, sold under the brand names Loxitane and Adasuve among others, is a tricyclic antipsychotic medication used primarily in the treatment of schizophrenia. The medicine is a member of the dibenzoxazepine class and structurally very similar to clozapine. Several researchers have argued that loxapine, initially classified as a typical antipsychotic, behaves as an atypical antipsychotic.

<span class="mw-page-title-main">National Institute for Health and Care Excellence</span> Non-departmental public body of the Department of Health in the UK

The National Institute for Health and Care Excellence (NICE) is an executive non-departmental public body of the Department of Health and Social Care.

<span class="mw-page-title-main">Institute of Psychiatry, Psychology and Neuroscience</span> Research institution in London, England

The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) is a centre for mental health and neuroscience research, education and training in Europe. It is dedicated to understanding, preventing and treating mental illness, neurological conditions, and other conditions that affect the brain. The IoPPN is a faculty of King's College London, England, and was previously known as the Institute of Psychiatry (IoP).

<span class="mw-page-title-main">Maudsley Hospital</span> Psychiatric hospital in London, England

The Maudsley Hospital is a British psychiatric hospital in south London. The Maudsley is the largest mental health training institution in the UK. It is part of South London and Maudsley NHS Foundation Trust, and works in partnership with the Institute of Psychiatry, King's College London. The hospital was one of the originating institutions in producing the Maudsley Prescribing Guidelines. It is part of the King's Health Partners academic health science centre and the National Institute for Health and Care Research (NIHR) Biomedical Research Centre for Mental Health.

<span class="mw-page-title-main">George Savage (physician)</span>

Sir George Henry Savage was a prominent English psychiatrist.

The Michael Rutter Centre for Children and Adolescents is based at the Maudsley Hospital, a psychiatric hospital run by the National Health Service NHS. Named after Sir Michael Rutter, it caters for children suffering from mental health issues such as anorexia. In 1994 it was estimated that at least 10% of children suffering from mental health problems required specialist facilities, but only 1-1.5% of children were being referred.. Parry-Jones described Child Mental Health Services as the 'Cinderella Service'.

<span class="mw-page-title-main">South London and Maudsley NHS Foundation Trust</span> NHS foundation trust based in London, England

South London and Maudsley NHS Foundation Trust, also known as SLaM, is an NHS foundation trust based in London, England, which specialises in mental health. It comprises four psychiatric hospitals, the Ladywell Unit based at University Hospital Lewisham, and over 100 community sites and 300 clinical teams. SLaM forms part of the institutions that make up King's Health Partners, an academic health science centre.

Oxleas NHS Foundation Trust is a National Health Service trust named after the ancient Oxleas Woods between Bexley and Greenwich.

Kevin Joseph Michael Gournay is a registered psychologist, chartered scientist and a registered nurse by background. He is an emeritus professor at the Institute of Psychiatry, Psychology and Neuroscience; King's College London. He was a consultant psychologist at the Priory Hospital North London; retiring in December 2018. He then returned to clinical work as part of the national response to COVID19; retiring once more in 2023. He is currently an Honorary Professor at the Matilda Centre; University of Sydney. His work in Australia spans 30 years to the present and focusses on the combination of mental health problems and substance use. During the COVID19 pandemic he contributed to research on the impacts of COVID19 on mental health. He has been responsible over many years for a very wide range of research, policy and practice development in mental health care. He also works as an Expert Witness; he has provided reports on more than 300 suicides; 20 homicides and hundreds of reports on people who have suffered the consequences of traumatic events, including accidents, terrorist related incidents, natural disasters, war related events and stillbirth and perinatal death. He has also provided numerous reports on patients receiving care and treatment in high secure and Medium secure settings, including Broadmoor, Rampton and Ashworth hospitals

Pamela Jane Taylor is a British psychiatrist and academic, who specialises in the links between psychosis and violence, and mental and physical health in the criminal justice system. Since 2004, she has been Professor of Forensic Psychiatry in the Department Institute of Psychological Medicine and Clinical Neurosciences of Cardiff University.

<span class="mw-page-title-main">National Collaborating Centre for Mental Health</span> Mental health collaboration

The National Collaborating Centre for Mental Health (NCCMH) is a collaboration between the Royal College of Psychiatrists and the Centre for Outcomes Research and Effectiveness at University College London (UCL). The NCCMH aims to promote the role of evidence synthesis in making informed judgments about healthcare policy. The NCCMH has a history of developing guidelines, conducting systematic reviews and developing implementation guidance for commissioners and service providers. Formed in 2001, on 1 April 2016 a new guideline development centre, the National Guideline Alliance, based at the Royal College of Obstetricians and Gynaecologists took over the clinical guideline programme that had been run by NCCMH.

<span class="mw-page-title-main">National Psychosis Unit</span> Hospital in England

The National Psychosis Unit is a national treatment centre for patients with schizophrenia and other psychotic disorders, in the United Kingdom. The unit is a tertiary referral centre in the National Health Service. It is located at the Bethlem Royal Hospital, part of the South London and Maudsley NHS Foundation Trust. It is closely affiliated to the Institute of Psychiatry, King's College London, and forms part of the Psychosis Clinical Academic Group of King's Health Partners.

<span class="mw-page-title-main">Amitriptyline/perphenazine</span> Combination drug

Amitriptyline/perphenazine is a formulation that contains the tricyclic antidepressant amitriptyline and the medium-potency typical (first-generation) antipsychotic, perphenazine. In the United States amitriptyline/perphenazine is marketed by Mylan Pharmaceuticals Inc. and Remedy Repack Inc.

<span class="mw-page-title-main">Philippa Garety</span> British psychologist

Philippa Garety is Professor of Clinical Psychology and Clinical Director of the Psychosis Clinical Academic Group (CAG), South London and Maudsley NHS Foundation Trust. Garety specializes in the psychological understanding and treatment of psychosis and, in particular, delusions.

<span class="mw-page-title-main">Elizabeth Kuipers</span>

Elizabeth Alice Kuipers is a professor of psychology at the Institute of Psychiatry, King's College London, and was head of the Psychology Department from 2006- 2012. Kuipers is a consultant clinical psychologist and until 2012, had an honorary appointment at the South London and Maudsley NHS Foundation Trust, working as part of the psychosis community mental health team in Southwark. She is a founding director of the PICuP clinic and was the chair of the NICE Schizophrenia Guideline update 2007-9 and the Psychosis and Schizophrenia update 2011-2014

Shubulade Smith, also known as Lade Smith is a British academic and consultant psychiatrist at the South London and Maudsley NHS Foundation Trust (SLaM). She is a senior lecturer at King's College, London and Clinical Director at the NCCMH and forensic services at SLaM, and is currently serving as the first black President of the Royal College of Psychiatrists.

<span class="mw-page-title-main">David Taylor (professor)</span>

David Taylor FFRPS FRPharmS is a British professor. He is the head of the Pharmaceutical Sciences Clinical Academic Group within King's Health Partners. Taylor has been lead author and editor of the Maudsley Prescribing Guidelines in Psychiatry since 1994. In 2014, Taylor was named as one of the top 100 clinical leaders in the UK National Health Service.

References

  1. 1 2 Toone B The Bethlem and Maudsley NHS Trust Prescribing Guidelines 1999, J Neurol Neurosurg Psychiatry, 68, London, 2000, p. 125
  2. ↑ Leonard B. "The Maudsley 2001 Maudsley Prescribing Guidelines (sixth edition) Book Review", Human Psychopharmacology: Clinical and Experimental , London, 2001. Retrieved on 11 March 2014.
  3. ↑ Szabadi E. "The Maudsley 2003 Prescribing Guidelines, 7th edition Book Review", British Journal of Clinical Pharmacology , London, 2004. Retrieved on 11 March 2014.
  4. ↑ Feetam C. "The Maudsley 2005-2006 Prescribing Guidelines (8th edn) Book Review", Psychiatric Bulletin , London, 2006. Retrieved on 11 March 2014.
  5. ↑ Jacobs GE, Cohen AF. "The South London and Maudsley NHS Foundation Trust and Oxleas NHS Foundation Trust Prescribing Guidelines, 9th Edition Book Review", British Journal of Clinical Pharmacology , London, 2008. Retrieved on 11 March 2014.
  6. ↑ Taylor D, Paon C, Kapur S. "The Maudsley Prescribing Guidelines Tenth Edition", Informa Healthcare , London, 2009. Retrieved on 11 March 2014.
  7. ↑ Taylor D, Paton C, Kapur S. "The Maudsley Prescribing Guidelines in Psychiatry, 11th Edition", Wiley Blackwell , London, 2012. Retrieved on 11 March 2014.
  8. ↑ Taylor D, Paton C, Kapur S. "The Maudsley Prescribing Guidelines in Psychiatry, 12th Edition", Wiley Blackwell , London, 2015. Retrieved on 17 June 2015.
  9. ↑ Reuters. "The Research and Markets: The Maudsley Prescribing Guidelines in Psychiatry, 11th Edition", Reuters , United States, 27 June 2012. Retrieved on 23 January 2014.
  10. ↑ "The Maudsley Prescribing Guidelines in Psychiatry, 13th Edition". Wiley.com. 18 May 2018. Retrieved 21 May 2018.
  11. ↑ "Conference 2018". maudsley-prescribing-guidelines.co.uk. Retrieved 5 June 2018.
  12. ↑ "The Maudsley Practice Guidelines for Physical Health Conditions in Psychiatry". Wiley.com. 1 October 2020. Retrieved 24 June 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.